![Sample our Bioscience journals, sign in here to start your access, Latest two full volumes FREE to you for 14 days]({"type":"image" , "src" : "/sda/5925/TOC-Subject-Sample-2021-Bioscience.jpg"})
Abstract
A number of important studies were presented at the Society for Neuro-Oncology annual meeting in Montréal, Canada, on 18–21 November 2010. Cediranib as monotherapy or in combination with lomustine did not show increased efficacy when compared with lomustine alone in patients with recurrent glioblastoma (GBM). Addition of temozolomide (TMZ) or irinotecan (CPT) to bevacizumab (BEV) in patients with recurrent GBM was well tolerated, with similar efficacy to BEV alone. The addition of BEV to radiation and TMZ in newly diagnosed GBM improved progression-free survival but did not improve overall survival. TMZ alone may be a reasonable approach in elderly GBM patients with poor performance status. Two Phase II trials with suntinib and vatalanib showed a hint of activity in patients with recurrent or progressive meningiomas.
Financial & competing interests disclosure
The author has no relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript. This includes employment, consultancies, honoraria, stock ownership or options, expert testimony, grants or patents received or pending, or royalties.
No writing assistance was utilized in the production of this manuscript.